Cure My Disease

Don't miss your cure!

 Log in / Sign up

Home workouts may ease Chemotherapy's toll on breast cancer patients

NCT ID NCT07716306

Symptom relief Sponsor: Riga Stradins University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study tests whether a 24-week, remotely supervised exercise program combining aerobic intervals and resistance training can improve physical health and quality of life in women with breast cancer undergoing chemotherapy. Participants, aged 30-65 with stage II-III breast cancer, will be randomly assigned to either the exercise group or a control group. The program uses a smartwatch, heart rate monitor, and resistance bands with sensors, with sessions three times per week. Researchers will measure changes in cardiorespiratory fitness, muscle strength, cognitive function, and side effects from chemotherapy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
remotely supervised combined aerobic high-intensity interval and resistance exercise training
What this could lead to
If effective, this approach could offer a convenient, home-based way to reduce chemotherapy side effects and improve quality of life for breast cancer patients.
What could go wrong
This is a small, early-stage trial with 60 participants, so results may not apply to all patients. Adherence to remote exercise may vary, and the intervention may not significantly reduce side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 65 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * previously untreated primary breast cancer; * stage IIA-B, IIIA-C at diagnosis; * diagnosis established by core needle biopsy; * age 30-65 years; * prescribed doxorubicin/cyclophosphamide-based NACT. Exclusion Criteria: * cardiac pathologies (assessed by echocardiogram); * blood transfusion in the last six months; * another oncological disease; * previous chemotherapy, hormonal or X-ray treatment; * participation in another clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Riga Stradins University

    Riga, LV1007, Latvia

More trials for these conditions

Other studies related to the condition(s) this trial covers.